Cite

HARVARD Citation

    Inagaki, Y. et al. (2020). Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'. Lung cancer. pp. 179-180. [Online]. 
  
Back to record